NCT01492036 Long-Term Follow-Up of Recipient of Gene Transfer Research
| NCT ID | NCT01492036 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Retroviridae Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2011-12-09 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2011-12-09 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical research study is to collect information about the long-term safety of gene transfer therapy. This study is also designed to create a database of medical information about patients who have received gene transfer therapy, in order for researchers to track and review the long-term safety and any effects (good or bad) of gene transfer therapy.
Eligibility Criteria
Inclusion Criteria: 1. Patient or patient's legal representative(s) provided written informed consent to participate in a gene transfer study at the University of Texas MD Anderson Cancer Center (MD Anderson). 2. Patient will receive vector or vector-treated cells at MD Anderson. 3. Patient or patient's legal representative(s) is/are able to provide written informed consent to participate in this long-term follow-up protocol for gene transfer participants for up to 15 years following administration of gene therapy product. 4. Agree to allow clinical samples to be collected and stored at MD Anderson and/or at a NIH designated facility such as the NGVB. Exclusion Criteria: 1\) Subject's gene transfer protocol is not approved at MD Anderson Cancer Center.
Contact & Investigator
Partow Kebriaei, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT01492036 clinical trial?
This trial is open to participants of all sexes, studying Retroviridae Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01492036 currently recruiting?
Yes, NCT01492036 is actively recruiting participants. Contact the research team at pkebriae@mdanderson.org for enrollment information.
Where is the NCT01492036 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT01492036 clinical trial?
NCT01492036 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Partow Kebriaei, MD at M.D. Anderson Cancer Center. The trial plans to enroll 130 participants.